Chronic Hepatitis C Virus Infection
Infectious Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
VP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PharmaEssentiaP1101 + Ribavirin
Vertex Pharmaceuticalstelaprevir
Clinical Trials (2)
Total enrollment: 152 patients across 2 trials
Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
Start: Jan 2016Est. completion: Jul 2020
Phase 3Completed
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
Start: Aug 2010Est. completion: Nov 2013152 patients
Phase 2Terminated
Related Jobs in Infectious Diseases
Senior Recruiter
Invivyd
New Haven, CT (Northeast preferred)
7h ago
$120K - $160K/yr
Senior Associate Scientist (contract), Upstream Polysaccharide Process Development
VaxCyte
San Carlos, California, United States
9h ago
$56/hr
Senior Associate Scientist (contract), Polysaccharide Analytical Development
VaxCyte
San Carlos, California, United States
10h ago
$56/hr
Director, Program Management
Metaphore Biotechnologies
Somerville, MA USA
13h ago
$179K - $237K/yr
Technician, Operations, DSP/ Technicien(ne) des opérations, DSP
Verona Pharma
CAN - Prince Edward Island - Charlottetown
Yesterday
$47K - $79K/yr
HVAC Maintenance Technician
Verona Pharma
USA - Delaware - Millsboro (Intervet)
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space